PCSK9 inhibitors reduce cardiovascular events in statin-treated patients
5 events · 2 assessments · 2 decisions
Reassessed
Triggered by subclaim_change: the core dependency "Randomized trials show PCSK9 inhibitors added to statin therapy reduce major cardiovascular events" became verified (0.95) on FOURIER and ODYSSEY OUTCOMES. This is the same trial evidence the parent already relied on, so the change is confirming, not directional. Kept status verified and nudged confidence 0.94 -> 0.95 to reflect that the pivotal-trial premise is now a verified node rather than an assumed one. No structural change: the decomposition (mechanism + LDL-proportionality + direct trials, one 'for' argument) still captures what the claim turns on, and no missing dependency surfaced. Importance left at 0.4 (notable/major clinical claim, but direction is settled and uncontested; the live debate is over magnitude/mortality/cost, which belongs to other claims). No dependent notification: status unchanged, so no dependent's verdict is put in question.
Reassessed: still Verified
verdict confidence 0.94 → 0.95 · credence 0.97
Structured and assessed
First pass. Decomposed into one 'for' argument grouping three subclaims: a new core trial-evidence subclaim (RCTs show PCSK9 inhibitors added to statins reduce major CV events, importance 0.4), a new mechanistic stub (PCSK9 inhibitors substantially lower LDL on top of statins, importance 0.15, left as deferred stub), and a link to the existing supported claim that non-statin LDL-lowering therapies reduce events proportionally to LDL reduction. Matcher confirmed both new subclaims novel. Set importance 0.4 (notable): clinically consequential but not a live crux, since event reduction is broadly accepted. Assessed VERIFIED (confidence 0.94, credence 0.97) on the strength of FOURIER (HR 0.85) and ODYSSEY OUTCOMES (HR 0.85), both in statin-treated patients, plus confirmatory web search of primary trial figures. Residual debate (absolute benefit size, mortality, cost) does not bear on whether events are reduced. Marginal yield low; further passes unlikely to change the verdict.
Assessed Verified
verdict confidence 0.94 · credence 0.97
Two large randomized, placebo-controlled outcome trials establish that adding a PCSK9 inhibitor to statin therapy reduces cardiovascular events. In FOURIER (27,564 patients with stable atherosclerotic disease on statins), evolocumab reduced the primary composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization by about 15% (hazard ratio 0.85), with a larger relative reduction on the harder secondary composite. In ODYSSEY OUTCOMES (around 18,900 patients after a recent acute coronary syndrome on intensive statin therapy), alirocumab reduced major adverse cardiovascular events by a similar margin (hazard ratio 0.85). The effect is consistent with the broader, well-established finding that lowering LDL cholesterol reduces cardiovascular events roughly in proportion to the reduction achieved, and PCSK9 inhibitors produce a large incremental LDL reduction on top of statins. The reduction in cardiovascular events is not in serious dispute among cardiologists. Live discussion instead concerns matters this claim does not assert: the modest absolute risk reduction over a few years of follow-up, the absence of a clear all-cause or cardiovascular mortality benefit in the individual trials, and cost-effectiveness relative to now-generic statins and ezetimibe. None of these bear on whether events are reduced, which both trials demonstrate directly.
Claim entered the graph